Oxygen Biotherapeutics signs CRADA with USAISR Oxygen Biotherapeutics has signed a Cooperative Research and Development Agreement, or CRADA, with the U.S. Army Institute of Surgical Research at Fort Sam Houston Texas to explore the potential effects of OBI’s proprietary perfluorocarbon-based emulsion, Oxycyte, on platelet function and blood hemostasis. This CRADA has been initiated to complement ongoing research and development work funded previously by a Department of Defense grant to broaden the safety profile of the use of perfluorocarbon-based emulsions to treat patients with traumatic brain injury – an indication for which OBI is conducting Phase II clinical trials overseas.
News For OXBT From The Last 14 Days
Check below for free stories on OXBT the last two weeks.
Subscribe for More Information